Correlation Between Stoke Therapeutics and Akero Therapeutics
Can any of the company-specific risk be diversified away by investing in both Stoke Therapeutics and Akero Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Stoke Therapeutics and Akero Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Stoke Therapeutics and Akero Therapeutics, you can compare the effects of market volatilities on Stoke Therapeutics and Akero Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Stoke Therapeutics with a short position of Akero Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Stoke Therapeutics and Akero Therapeutics.
Diversification Opportunities for Stoke Therapeutics and Akero Therapeutics
0.33 | Correlation Coefficient |
Weak diversification
The 3 months correlation between Stoke and Akero is 0.33. Overlapping area represents the amount of risk that can be diversified away by holding Stoke Therapeutics and Akero Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Akero Therapeutics and Stoke Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Stoke Therapeutics are associated (or correlated) with Akero Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Akero Therapeutics has no effect on the direction of Stoke Therapeutics i.e., Stoke Therapeutics and Akero Therapeutics go up and down completely randomly.
Pair Corralation between Stoke Therapeutics and Akero Therapeutics
Given the investment horizon of 90 days Stoke Therapeutics is expected to generate 3.41 times less return on investment than Akero Therapeutics. But when comparing it to its historical volatility, Stoke Therapeutics is 5.28 times less risky than Akero Therapeutics. It trades about 0.38 of its potential returns per unit of risk. Akero Therapeutics is currently generating about 0.25 of returns per unit of risk over similar time horizon. If you would invest 2,661 in Akero Therapeutics on November 8, 2024 and sell it today you would earn a total of 3,095 from holding Akero Therapeutics or generate 116.31% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 95.24% |
| Values | Daily Returns |
Stoke Therapeutics vs. Akero Therapeutics
Performance |
| Timeline |
| Stoke Therapeutics |
| Akero Therapeutics |
Stoke Therapeutics and Akero Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Stoke Therapeutics and Akero Therapeutics
The main advantage of trading using opposite Stoke Therapeutics and Akero Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Stoke Therapeutics position performs unexpectedly, Akero Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will offset losses from the drop in Akero Therapeutics' long position.| Stoke Therapeutics vs. Adaptimmune Therapeutics Plc | Stoke Therapeutics vs. Black Diamond Therapeutics | Stoke Therapeutics vs. Relay Therapeutics | Stoke Therapeutics vs. Pliant Therapeutics |
| Akero Therapeutics vs. Terns Pharmaceuticals | Akero Therapeutics vs. Madrigal Pharmaceuticals | Akero Therapeutics vs. Inozyme Pharma | Akero Therapeutics vs. Viking Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Complementary Tools
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |